1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan

1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan

Introduction: Similar to the US, Japan has seen a decline in sulfonylureas (SUs) use in the elderly patients (pts) with diabetes, but the detailed usage status of SU is unknown. Methods: To investigate real-world SU prescribing patterns, we conducted a retrospective cross-sectional survey using phar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1
Hauptverfasser: SAKAMOTO, MASAYA, YAMAZAKI, MICHIKO, TAKEBE, TOHRU, HOSOKAWA, MASAYA, SAIKA, TOMOYA, NAKAO, YUTAKA, IKEDA, SHUNYA
Format: Artikel
Sprache:eng
Schlagworte:
Diabetes
Diabetes mellitus
Glibenclamide
Hypoglycemia
Sulfonylurea
Surveys
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page 1
container_title Diabetes (New York, N.Y.)
container_volume 73
creator SAKAMOTO, MASAYA
YAMAZAKI, MICHIKO
TAKEBE, TOHRU
HOSOKAWA, MASAYA
SAIKA, TOMOYA
NAKAO, YUTAKA
IKEDA, SHUNYA
description Introduction: Similar to the US, Japan has seen a decline in sulfonylureas (SUs) use in the elderly patients (pts) with diabetes, but the detailed usage status of SU is unknown. Methods: To investigate real-world SU prescribing patterns, we conducted a retrospective cross-sectional survey using pharmacy data in Japan, targeting pts prescribed SUs, aged 20-100 years. From November 2022 to October 2023, we extracted data for 91,230 pts from the electronic prescription system Musubi (KAKEHASHI Inc., adopted in over 7,000 pharmacies, accounting for 10% market share, as of 2023 in Japan). The most commonly prescribed SUs were glimepiride (73,061 pts, 80.1%), gliclazide (14,841 pts, 16.3%), and glibenclamide (3,327 pts, 3.6%). Our analysis focused on adherence to Japanese guidelines in prescribing these SUs in elderly pts (adhering to limits of 1 mg/day for glimepiride and 40 mg/day for gliclazide, and avoiding glibenclamide). Results: Of 91,230 pts showed 55,947 were male (61.3%) and a mean age of 68.8 years; 66,319 (72.7%) were aged ≥65 years. Elderly pts on average used 2.7 antidiabetic medications concurrently. The most common additional medications with SUs were DPP-4 inhibitor (49,963 pts, 75.3%), biguanide (34,266 pts, 61.2%), and SGLT-2 inhibitor (25,878 pts, 46.3%). Insulin was used concomitantly in 3,682 elderly pts (6.6%). Among elderly pts, 25.0% and 7.8% exceeded the recommended dosages for glimepiride (>1 mg/day) and gliclazide (>40 mg/day), respectively. Glibenclamide was prescribed to 2,578 elderly pts (77.5%). However, elderly pts used fewer diabetes medications on average: 3.3 for those
doi_str_mv 10.2337/db24-1255-P
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3111273828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111273828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c648-52e9d41be17c4c8534aaba15c89c326062b7fa60589ac35ab38aef8da35392da3</originalsourceid><addsrcrecordid>eNotkMtKxDAUhoMoOF5WvkDApURzaaapO5kZbwxYdER34TRNNUNsa9IqfXtbRs7i33z_OYcPoTNGL7kQ6VVZ8IQwLiXJ99CMZSIjgqfv-2hGKeOEpVl6iI5i3FJK5-PMkNvR1_il91VTD74PFnAebDTBtZ1rauxqvPKlDX7AOXTO1l3Ev677xEsHhe1sHLvhxw74Nbr6Az9b8OStCb7ES-hgqj9CC_UJOqjAR3v6n8doc7vaLO7J-unuYXGzJmaeKCK5zcqEFZalJjFKigSgACaNyozg48-8SCuYU6kyMEJCIRTYSpUgpMj4GMfofLe2Dc13b2Ont00f6vGiFowxngrF1Uhd7CgTmhiDrXQb3BeEQTOqJ5V6UqknOToXfyX5Zi4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111273828</pqid></control><display><type>article</type><title>1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>SAKAMOTO, MASAYA ; YAMAZAKI, MICHIKO ; TAKEBE, TOHRU ; HOSOKAWA, MASAYA ; SAIKA, TOMOYA ; NAKAO, YUTAKA ; IKEDA, SHUNYA</creator><creatorcontrib>SAKAMOTO, MASAYA ; YAMAZAKI, MICHIKO ; TAKEBE, TOHRU ; HOSOKAWA, MASAYA ; SAIKA, TOMOYA ; NAKAO, YUTAKA ; IKEDA, SHUNYA</creatorcontrib><description>Introduction: Similar to the US, Japan has seen a decline in sulfonylureas (SUs) use in the elderly patients (pts) with diabetes, but the detailed usage status of SU is unknown. Methods: To investigate real-world SU prescribing patterns, we conducted a retrospective cross-sectional survey using pharmacy data in Japan, targeting pts prescribed SUs, aged 20-100 years. From November 2022 to October 2023, we extracted data for 91,230 pts from the electronic prescription system Musubi (KAKEHASHI Inc., adopted in over 7,000 pharmacies, accounting for 10% market share, as of 2023 in Japan). The most commonly prescribed SUs were glimepiride (73,061 pts, 80.1%), gliclazide (14,841 pts, 16.3%), and glibenclamide (3,327 pts, 3.6%). Our analysis focused on adherence to Japanese guidelines in prescribing these SUs in elderly pts (adhering to limits of 1 mg/day for glimepiride and 40 mg/day for gliclazide, and avoiding glibenclamide). Results: Of 91,230 pts showed 55,947 were male (61.3%) and a mean age of 68.8 years; 66,319 (72.7%) were aged ≥65 years. Elderly pts on average used 2.7 antidiabetic medications concurrently. The most common additional medications with SUs were DPP-4 inhibitor (49,963 pts, 75.3%), biguanide (34,266 pts, 61.2%), and SGLT-2 inhibitor (25,878 pts, 46.3%). Insulin was used concomitantly in 3,682 elderly pts (6.6%). Among elderly pts, 25.0% and 7.8% exceeded the recommended dosages for glimepiride (&gt;1 mg/day) and gliclazide (&gt;40 mg/day), respectively. Glibenclamide was prescribed to 2,578 elderly pts (77.5%). However, elderly pts used fewer diabetes medications on average: 3.3 for those &lt;65 years, 3.0 for 65-&lt;75 years, and 2.7 for ≥75 years. Conclusion: We identified high-dose prescription of glimepiride and gliclazide, and glibenclamide use in elderly pts, indicating potential non-adherence to guidelines. Our findings highlight the need for enhanced education and appropriate SU usage to prevent hypoglycemia and diabetic complications.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-1255-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Diabetes ; Diabetes mellitus ; Glibenclamide ; Hypoglycemia ; Sulfonylurea ; Surveys</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>SAKAMOTO, MASAYA</creatorcontrib><creatorcontrib>YAMAZAKI, MICHIKO</creatorcontrib><creatorcontrib>TAKEBE, TOHRU</creatorcontrib><creatorcontrib>HOSOKAWA, MASAYA</creatorcontrib><creatorcontrib>SAIKA, TOMOYA</creatorcontrib><creatorcontrib>NAKAO, YUTAKA</creatorcontrib><creatorcontrib>IKEDA, SHUNYA</creatorcontrib><title>1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan</title><title>Diabetes (New York, N.Y.)</title><description>Introduction: Similar to the US, Japan has seen a decline in sulfonylureas (SUs) use in the elderly patients (pts) with diabetes, but the detailed usage status of SU is unknown. Methods: To investigate real-world SU prescribing patterns, we conducted a retrospective cross-sectional survey using pharmacy data in Japan, targeting pts prescribed SUs, aged 20-100 years. From November 2022 to October 2023, we extracted data for 91,230 pts from the electronic prescription system Musubi (KAKEHASHI Inc., adopted in over 7,000 pharmacies, accounting for 10% market share, as of 2023 in Japan). The most commonly prescribed SUs were glimepiride (73,061 pts, 80.1%), gliclazide (14,841 pts, 16.3%), and glibenclamide (3,327 pts, 3.6%). Our analysis focused on adherence to Japanese guidelines in prescribing these SUs in elderly pts (adhering to limits of 1 mg/day for glimepiride and 40 mg/day for gliclazide, and avoiding glibenclamide). Results: Of 91,230 pts showed 55,947 were male (61.3%) and a mean age of 68.8 years; 66,319 (72.7%) were aged ≥65 years. Elderly pts on average used 2.7 antidiabetic medications concurrently. The most common additional medications with SUs were DPP-4 inhibitor (49,963 pts, 75.3%), biguanide (34,266 pts, 61.2%), and SGLT-2 inhibitor (25,878 pts, 46.3%). Insulin was used concomitantly in 3,682 elderly pts (6.6%). Among elderly pts, 25.0% and 7.8% exceeded the recommended dosages for glimepiride (&gt;1 mg/day) and gliclazide (&gt;40 mg/day), respectively. Glibenclamide was prescribed to 2,578 elderly pts (77.5%). However, elderly pts used fewer diabetes medications on average: 3.3 for those &lt;65 years, 3.0 for 65-&lt;75 years, and 2.7 for ≥75 years. Conclusion: We identified high-dose prescription of glimepiride and gliclazide, and glibenclamide use in elderly pts, indicating potential non-adherence to guidelines. Our findings highlight the need for enhanced education and appropriate SU usage to prevent hypoglycemia and diabetic complications.</description><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Glibenclamide</subject><subject>Hypoglycemia</subject><subject>Sulfonylurea</subject><subject>Surveys</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNotkMtKxDAUhoMoOF5WvkDApURzaaapO5kZbwxYdER34TRNNUNsa9IqfXtbRs7i33z_OYcPoTNGL7kQ6VVZ8IQwLiXJ99CMZSIjgqfv-2hGKeOEpVl6iI5i3FJK5-PMkNvR1_il91VTD74PFnAebDTBtZ1rauxqvPKlDX7AOXTO1l3Ev677xEsHhe1sHLvhxw74Nbr6Az9b8OStCb7ES-hgqj9CC_UJOqjAR3v6n8doc7vaLO7J-unuYXGzJmaeKCK5zcqEFZalJjFKigSgACaNyozg48-8SCuYU6kyMEJCIRTYSpUgpMj4GMfofLe2Dc13b2Ont00f6vGiFowxngrF1Uhd7CgTmhiDrXQb3BeEQTOqJ5V6UqknOToXfyX5Zi4</recordid><startdate>20240614</startdate><enddate>20240614</enddate><creator>SAKAMOTO, MASAYA</creator><creator>YAMAZAKI, MICHIKO</creator><creator>TAKEBE, TOHRU</creator><creator>HOSOKAWA, MASAYA</creator><creator>SAIKA, TOMOYA</creator><creator>NAKAO, YUTAKA</creator><creator>IKEDA, SHUNYA</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240614</creationdate><title>1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan</title><author>SAKAMOTO, MASAYA ; YAMAZAKI, MICHIKO ; TAKEBE, TOHRU ; HOSOKAWA, MASAYA ; SAIKA, TOMOYA ; NAKAO, YUTAKA ; IKEDA, SHUNYA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c648-52e9d41be17c4c8534aaba15c89c326062b7fa60589ac35ab38aef8da35392da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Glibenclamide</topic><topic>Hypoglycemia</topic><topic>Sulfonylurea</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAKAMOTO, MASAYA</creatorcontrib><creatorcontrib>YAMAZAKI, MICHIKO</creatorcontrib><creatorcontrib>TAKEBE, TOHRU</creatorcontrib><creatorcontrib>HOSOKAWA, MASAYA</creatorcontrib><creatorcontrib>SAIKA, TOMOYA</creatorcontrib><creatorcontrib>NAKAO, YUTAKA</creatorcontrib><creatorcontrib>IKEDA, SHUNYA</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAKAMOTO, MASAYA</au><au>YAMAZAKI, MICHIKO</au><au>TAKEBE, TOHRU</au><au>HOSOKAWA, MASAYA</au><au>SAIKA, TOMOYA</au><au>NAKAO, YUTAKA</au><au>IKEDA, SHUNYA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-14</date><risdate>2024</risdate><volume>73</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Introduction: Similar to the US, Japan has seen a decline in sulfonylureas (SUs) use in the elderly patients (pts) with diabetes, but the detailed usage status of SU is unknown. Methods: To investigate real-world SU prescribing patterns, we conducted a retrospective cross-sectional survey using pharmacy data in Japan, targeting pts prescribed SUs, aged 20-100 years. From November 2022 to October 2023, we extracted data for 91,230 pts from the electronic prescription system Musubi (KAKEHASHI Inc., adopted in over 7,000 pharmacies, accounting for 10% market share, as of 2023 in Japan). The most commonly prescribed SUs were glimepiride (73,061 pts, 80.1%), gliclazide (14,841 pts, 16.3%), and glibenclamide (3,327 pts, 3.6%). Our analysis focused on adherence to Japanese guidelines in prescribing these SUs in elderly pts (adhering to limits of 1 mg/day for glimepiride and 40 mg/day for gliclazide, and avoiding glibenclamide). Results: Of 91,230 pts showed 55,947 were male (61.3%) and a mean age of 68.8 years; 66,319 (72.7%) were aged ≥65 years. Elderly pts on average used 2.7 antidiabetic medications concurrently. The most common additional medications with SUs were DPP-4 inhibitor (49,963 pts, 75.3%), biguanide (34,266 pts, 61.2%), and SGLT-2 inhibitor (25,878 pts, 46.3%). Insulin was used concomitantly in 3,682 elderly pts (6.6%). Among elderly pts, 25.0% and 7.8% exceeded the recommended dosages for glimepiride (&gt;1 mg/day) and gliclazide (&gt;40 mg/day), respectively. Glibenclamide was prescribed to 2,578 elderly pts (77.5%). However, elderly pts used fewer diabetes medications on average: 3.3 for those &lt;65 years, 3.0 for 65-&lt;75 years, and 2.7 for ≥75 years. Conclusion: We identified high-dose prescription of glimepiride and gliclazide, and glibenclamide use in elderly pts, indicating potential non-adherence to guidelines. Our findings highlight the need for enhanced education and appropriate SU usage to prevent hypoglycemia and diabetic complications.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-1255-P</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1
issn 0012-1797
1939-327X
language eng
recordid cdi_proquest_journals_3111273828
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Diabetes
Diabetes mellitus
Glibenclamide
Hypoglycemia
Sulfonylurea
Surveys
title 1255-P: Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1255-P:%20Sulfonylurea%20Prescription%20in%20Elderly%20Patients%20with%20Diabetes%20Survey%20Using%20Real-World%20Data%20in%20Japan&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=SAKAMOTO,%20MASAYA&rft.date=2024-06-14&rft.volume=73&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-1255-P&rft_dat=%3Cproquest_cross%3E3111273828%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111273828&rft_id=info:pmid/&rfr_iscdi=true